Pfizer Inc (PFE)
NYSE:PFE
Top Page
Pfizer
(NYSE:PFE)
Select Model
Select Model
Rating:64Neutral
Price Target:
$29.00
▲(2.40% Upside)
Action:DowngradedDate:02/27/26
The score is primarily constrained by only mid-level financial performance (volatile revenues, lower cash flow than prior peaks, and elevated leverage). Offsetting this, technicals are constructive with price above key moving averages and positive MACD, and shareholder yield is attractive. Earnings-call commentary is moderately positive on guidance and productivity/pipeline progress, but tempered by COVID and LOE headwinds plus GAAP volatility.
Positive Factors
Regulatory approval expands oncology franchise
The FDA approval of encorafenib in combination regimens converts an accelerated approval into a full, tradable commercial indication for metastatic BRAF V600E colorectal cancer, enlarging Pfizer’s oncology addressable market, strengthening durable revenue streams and commercial presence in a high‑unmet area.
Negative Factors
Elevated leverage versus prior years
Leverage materially increased from 2021–2022 levels, leaving less financial flexibility. Higher debt burdens raise interest and refinancing risk, constrain M&A or buyback optionality if earnings soften, and reduce the company’s cushion against operational or portfolio shocks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approval expands oncology franchise
The FDA approval of encorafenib in combination regimens converts an accelerated approval into a full, tradable commercial indication for metastatic BRAF V600E colorectal cancer, enlarging Pfizer’s oncology addressable market, strengthening durable revenue streams and commercial presence in a high‑unmet area.
Read all positive factors
Pfizer (PFE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$156.20B
Dividend Yield6.65%
Average Volume (3M)38.69M
Price to Earnings (P/E)18.2
Beta (1Y)0.44
Revenue Growth-1.65%
EPS Growth-3.74%
CountryUS
Employees81,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.66
Shares Outstanding5,686,267,600
10 Day Avg. Volume32,274,283
30 Day Avg. Volume38,688,749
Financial Highlights & Ratios
PEG Ratio-4.31
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue3.56
Enterprise Value/Gross Profit5.06
Enterprise Value/Ebitda13.26
Forecast
1Y Price Target
$28.97Price Target Upside2.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)2.96
Revenue Forecast (FY)$61.17B
Pfizer Business Overview & Revenue Model
Company Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Pre...
How the Company Makes Money
Pfizer primarily generates revenue through the sale of prescription pharmaceuticals and vaccines. The company’s revenue model is supported by a diverse range of products across multiple therapeutic areas, allowing it to capitalize on various marke...
Pfizer Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Pfizer is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Pfizer is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyPfizer Earnings Call Summary
Earnings Call Date:Feb 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call presented multiple strong positives — better‑than‑expected adjusted EPS, margin expansion, meaningful cost‑savings realization, promising obesity (PF‑3944) clinical readouts with differentiated monthly dosing, robust activity on pivotal studies and approvals, and strategic acquisitions that are already contributing revenue growth. Offsetting these strengths are near‑term challenges: modest overall revenue decline (driven largely by a pronounced COVID revenue drop), a sizable $4.4 billion impairment reflecting portfolio reprioritization, upcoming LOE pressure (including ~ $1.5 billion revenue compression projected in 2026), and some GAAP volatility in the quarter. On balance, the company reinforced a clear strategic plan, reaffirmed 2026 guidance, and emphasized productivity/AI initiatives and reinvestment into high‑impact R&D, suggesting the positives materially outweigh the near‑term negatives.Positive Updates
Exceeded Financial Expectations and Shareholder Returns
Full year 2025 adjusted diluted EPS of $3.22 versus $3.11 in 2024 (ahead of expectations); returned $9.8 billion to shareholders via dividends; invested $10.4 billion in internal R&D and ~$8.8 billion in business development.
Negative Updates
Overall Revenue Decline Year‑over‑Year
Full year 2025 revenues were $62.6 billion versus $63.6 billion in 2024, representing a 2% operational decline; Q4 2025 revenues were $17.6 billion, a 3% operational decline versus prior year.
Read all updates
Q4-2025 Updates
Positive
Negative
Exceeded Financial Expectations and Shareholder Returns
Full year 2025 adjusted diluted EPS of $3.22 versus $3.11 in 2024 (ahead of expectations); returned $9.8 billion to shareholders via dividends; invested $10.4 billion in internal R&D and ~$8.8 billion in business development.
Read all positive updates
Company Guidance
Pfizer reaffirmed full‑year 2026 guidance calling for total revenues of $59.5–$62.5 billion and adjusted diluted EPS of $2.80–$3.00, with a mid‑seventies adjusted gross margin; management expects COVID‑19 product revenues to fall to about $5 billion and anticipates roughly $1.5 billion of 2026 revenue compression from products facing generic entry, while revenues at the midpoint excluding COVID and LOE products are expected to grow ~4% operationally. For context, full‑year 2025 revenues were $62.6 billion with adjusted diluted EPS of $3.22 and adjusted gross margin of 76%; Q4 revenues were $17.6 billion (−3% operationally) with non‑COVID Q4 growth of 9% and an approximate 40% Q4 COVID decline. Pfizer said it remains on track to deliver the majority of $7.2 billion in productivity savings by 2026, achieve $5.7 billion of cost‑realignment net savings by 2026, and add $700 million of manufacturing program savings in 2026 (and $200 million in 2027) toward a $1.5 billion total by 2027; it also noted ~ $7 billion of BD capacity (including expected VIVE proceeds), returned $9.8 billion in dividends in 2025, and invested $10.4 billion in internal R&D and ~$8.8 billion in business development in 2025.Pfizer Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
58
Neutral
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 62.58B | 63.63B | 59.55B | 100.33B | 81.29B |
| Gross Profit | 44.01B | 41.85B | 30.34B | 62.09B | 46.88B |
| EBITDA | 15.10B | 18.13B | 9.56B | 41.03B | 30.79B |
| Net Income | 7.77B | 8.02B | 2.13B | 31.36B | 22.15B |
Balance Sheet | |||||
| Total Assets | 208.16B | 213.40B | 226.50B | 197.21B | 181.48B |
| Cash, Cash Equivalents and Short-Term Investments | 13.60B | 20.48B | 12.69B | 22.73B | 31.07B |
| Total Debt | 67.42B | 66.99B | 70.84B | 34.86B | 37.00B |
| Total Liabilities | 121.39B | 124.90B | 137.21B | 101.29B | 104.01B |
| Stockholders Equity | 86.48B | 88.20B | 89.01B | 95.66B | 77.20B |
Cash Flow | |||||
| Free Cash Flow | 9.08B | 9.84B | 4.79B | 26.03B | 29.87B |
| Operating Cash Flow | 11.71B | 12.74B | 8.70B | 29.27B | 32.58B |
| Investing Cash Flow | -1.35B | 2.65B | -32.28B | -15.78B | -22.55B |
| Financing Cash Flow | -10.30B | -17.14B | 26.07B | -14.83B | -9.82B |
Pfizer Technical Analysis
Positive
28.32
Price Trends
27.10
Positive
26.06
Positive
24.95
Positive
Market Momentum
0.23
Positive
51.45
Neutral
37.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Positive. The current price of 28.32 is above the 20-day moving average (MA) of 27.36, above the 50-day MA of 27.10, and above the 200-day MA of 24.95, indicating a bullish trend. The MACD of 0.23 indicates Positive momentum. The RSI at 51.45 is Neutral, neither overbought nor oversold. The STOCH value of 37.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PFE.
Pfizer Risk Analysis
Pfizer disclosed 26 risk factors in its most recent earnings report. Pfizer reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pfizer Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $279.53B | 19.02 | 32.80% | 2.87% | 11.53% | -15.21% | |
73 Outperform | $581.20B | 18.81 | 33.78% | 2.50% | 6.05% | ― | |
71 Outperform | $188.57B | 22.84 | 96.65% | 3.00% | 10.56% | 88.13% | |
68 Neutral | $304.55B | 14.46 | 36.19% | 3.12% | 1.49% | 7.89% | |
64 Neutral | $156.20B | 18.21 | 8.67% | 6.65% | -1.65% | -3.74% | |
63 Neutral | $374.13B | 96.82 | -361.58% | 2.87% | 7.40% | -53.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PFE
Pfizer
27.47
6.50
31.01%
AMGN
Amgen
349.81
67.57
23.94%
JNJ
Johnson & Johnson
241.30
94.42
64.29%
MRK
Merck & Company
123.18
44.14
55.85%
NVS
Novartis
154.42
52.56
51.61%
ABBV
AbbVie
211.59
37.59
21.60%
Pfizer Corporate Events
Business Operations and StrategyFinancial Disclosures
Pfizer Revises 2025 Revenue Guidance to $62 Billion
Neutral
Dec 16, 2025
On December 16, 2025, Pfizer announced its financial guidance for the full year 2026, while revising its 2025 revenue guidance to approximately $62.0 billion. The company expects 2026 revenues to range between $59.5 and $62.5 billion, with a decre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.